Overview of botulinum neurotoxins

References

• Scott A. B. Development of botulinum toxin therapy. Dermatol Clin 2004; 22: 131–3
   PubMed Web of Science ®Google Scholar
• Scott A. B., Rosenbaum A., Collins C. C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973; 12: 924–7
   PubMedGoogle Scholar
• Scott A. B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044–9
   PubMed Web of Science ®Google Scholar
• Carruthers J. D., Carruthers J. A. Treatment of glabellar frown lines with C. Botulinum‐A exotoxin. J Dermatol Surg Oncol 1992; 18: 17–21
   PubMed Web of Science ®Google Scholar
• Keen M., Blitzer A., Aviv J., et al. Botulinum toxin A for hyperkinetic facial lines: results of a double‐blind, placebo‐controlled study. Plast Reconstr Surg 1994; 94: 94–9
   PubMed Web of Science ®Google Scholar
• Lowe N. J., Maxwell A., Harper H. Botulinum A exotoxin for glabellar folds: a double‐blind, placebo‐controlled study with an electromyographic injection technique. J Am Acad Dermatol 1996; 35: 569–72
   PubMedGoogle Scholar
• Carruthers J. D., Lowe N. J., Menter M. A., , for the BOTOX Glabellar Lines II Study Group, et al. Double‐blind, placebo‐controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112: 1089–98
   PubMed Web of Science ®Google Scholar
• Carruthers J. A., Lowe N. J., Menter M. A., , for the BOTOX Glabellar Lines I Study Group, et al. A multicenter, double‐blind, randomized, placebo‐controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840–9
   PubMed Web of Science ®Google Scholar
• Lowe N. J., Ascher B., Heckmann M., , for the Botox Facial Aesthetics Study Team, et al. Double‐blind, randomized, placebo‐controlled, dose‐response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31: 257–62
   PubMed Web of Science ®Google Scholar
• Kane M. A. The effect of botulinum toxin injections on the nasolabial fold. Plast Reconstr Surg 2003; 112( 5 suppl)66S–72S, discussion 73S–74S
   Google Scholar
• Flynn T. C., Carruthers J. A., Carruthers J. A., Clark R. E II. Botulinum A toxin (BOTOX) in the lower eyelid: dose‐finding study. Dermatol Surg 2003; 29: 943–50, discussion 950–1
   PubMed Web of Science ®Google Scholar
• Lowe N. J., Yamauchi P. S., Lask G. P., et al. Botulinum toxin types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002; 4: 15–8
   PubMedGoogle Scholar
• Ascher B., Zakine B., Kestemont P., et al. A multicenter, randomized, double‐blind, placebo‐controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223–33
   PubMed Web of Science ®Google Scholar
• BOTOX COSMETIC [prescribing information]. Allergan, Inc, Irvine, (CA) 2005
   Google Scholar
• Lowe P., Patnaik R., Lowe N. Comparison of two formulations of botulinum type A for the treatment of glabellar lines: a double‐blind, randomized study. J Am Acad Dermatol 2006; 55: 975–80
   PubMed Web of Science ®Google Scholar
• Lew H., Yun Y. S., Lee S. Y., Kim S. J. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica 2002; 216: 50–4
   PubMed Web of Science ®Google Scholar
• Jost W. H., Kohl A., Brinkmann S., Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm 2005; 112: 905–13
   PubMed Web of Science ®Google Scholar
• Roggenkämper P., Jost W. H., Bihari K., , for the NT 201 Blepharospasm Study Team, et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303–12
   PubMed Web of Science ®Google Scholar
• Bhidayasiri R., Cardoso F., Truong D. D. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 2006; 13(suppl 1)21–9
   Web of Science ®Google Scholar
• Tang X., Wan X. Comparison of BOTOX with a Chinese type A botulinum toxin. Chin Med J 2000; 113: 794–8
   PubMed Web of Science ®Google Scholar
• Rieder C. R., Schestatsky P., Socal M. P., et al. A double‐blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 2007; 30: 39–42
   PubMed Web of Science ®Google Scholar
• Flynn T. C., Carruthers J. A., Carruthers J. A. Botulinum‐A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001; 27: 703–8
   PubMed Web of Science ®Google Scholar
• Carruthers J., Fagien S., Matarasso S. L., and the Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 2004; 114(6 suppl)1S–22S
   Google Scholar
• Ahn M. S., Catten M., Maas C. S. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg 2000; 105: 1129–35
   PubMed Web of Science ®Google Scholar
• Rzany B., Ascher B., Fratila A., et al. Efficacy and safety of 3‐ and 5‐injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142: 320–6
   PubMedGoogle Scholar
• Trindade de Almeida A. R., Marques E., de Almeida J., et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33(special issue)S37–S43
   Google Scholar
• Heckmann M., Plewig G., for the Hyperhidrosis Study Group. Low‐dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side‐by‐side, open‐label study. Arch Dermatol 2005; 141: 1255–9
   PubMed Web of Science ®Google Scholar
• Sycha T., Kotzailias N., Kranz G., et al. UV‐B irradiation attenuates dermal effects of botulinum toxin A: a randomized, double‐blind, placebo‐controlled study. Dermatol Surg 2007; 33(special issue)S92–S96
   Google Scholar